丽珠医药(01513.HK)斥15.78亿人民币收购越南同业64.81%

阿斯达克财经
22 May

丽珠医药(01513.HK) 公布进一步拓展海外市场,向独立第三方SK Investment、Sunrise及KBA收购一家越南上市公司Imexpharm Corporation合共64.81%股权,后者主要从事药品的研发、生产和销售,产品主要包括抗生素、心脑血管药物等,现金代价57.31亿越南盾(约15.87亿人民币),将以内部资源拨付。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-05-22 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10